We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Successful treatment of atopic dermatitis refractory to dupilumab with baricitinib.
- Authors
Lee, Dong Heon; Park, So Yun; Hong, Narang; Kook, Hyung Don; Jung, Hye Jung; Park, Mi Youn; Ahn, Jiyoung
- Abstract
Atopic dermatitis (AD) is the most common chronic inflammatory skin disorder worldwide. In our recent report into AD patients with insufficient response to dupilumab, indeed, baricitinib was revealed as an effective add-on therapy for acute aggravation or further improvement.9 In addition to add-on therapy, baricitinib treatment alone can be effective for dupilumab-refractory AD patients, which can also prevent unnecessary adverse events of dupilumab. After 2 weeks of the baricitinib treatment, all the patient-oriented AD control tools improved.
- Subjects
DUPILUMAB; ATOPIC dermatitis; BARICITINIB; TREATMENT effectiveness; HERPES simplex
- Publication
Dermatologic Therapy, 2022, Vol 35, Issue 11, p1
- ISSN
1396-0296
- Publication type
Article
- DOI
10.1111/dth.15802